Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

CLOZAPINE

All strengths: Off-Formulary Interchangeable, not an ODB benefit; same patient cost rules

Shared coverage and patient cost rules
StatusOff-Formulary Interchangeable, not an ODB benefit
Patient paysPatient pays: program not supplied; amount cannot be determined.

Other products in the same Health Canada class (N05A, N05AH) — coverage varies; not interchangeable

  • Asenapine (Saphris): general benefit
  • Loxapine (Loxapac): general benefit, Not a benefit
  • Olanzapine (Zyprexa Zydis): general benefit, Not a benefit
  • Quetiapine (Seroquel XR): general benefit, Not a benefit
  • Aripiprazole (Abilify Asimtufii): general benefit
  • Brexpiprazole (Rexulti): general benefit

18 more in the class list below

AA-Clozapine Tablet · DIN 02248034 · 25mg ·

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Special Drugs ProgramSpecial Drugs Program: Clozapine for treatment of schizophrenia (ontario.ca, Updated 2023-07-13 ↗) Through the Special Drugs Program, the Ministry of Health covers the full cost of certain outpatient drugs used in the treatment of specific conditions. (ontario.ca, Updated 2023-07-13 ↗) The Special Drugs Program will cover costs for the above drugs if the patient: is an Ontario resident has a valid Ontario Health Insurance (OHIP) has one of the diseases or conditions covered meets the established clinical criteria is under the care of an approved physician/designated care centre (ontario.ca, Updated 2023-07-13 ↗)
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
AA-Clozapine Tablet · DIN 02248034 Manufacturer: A A Pharma Inc.; listing date 2007-09-04 Health Canada: Marketed since 2016-11-21 · brand AA-CLOZAPINE · ATC N05AH02 CLOZAPINE · form Tablet · route Oral · ingredients CLOZAPINE 25 MG · company Aa pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=72354 · Verify on the e-Formulary ↗ (DIN 02248034)

Source record
DIN 02248034: AA-Clozapine Tablet Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 281608157; group id 486; item number 1242; lccId None; manufacturer id AAP Source form: None; strength: 25mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $0.6594; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02248034 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=72354
Interchangeable products
Clozaril Tablet · DIN 00894737 · not recorded Gen-Clozapine ODT · DIN 02554658 · not recorded Gen-Clozapine Tablet · DIN 02247243 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02248034
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Clozaril Tablet · DIN 00894737 · 25mg ·

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Special Drugs ProgramSpecial Drugs Program: Clozapine for treatment of schizophrenia (ontario.ca, Updated 2023-07-13 ↗) Through the Special Drugs Program, the Ministry of Health covers the full cost of certain outpatient drugs used in the treatment of specific conditions. (ontario.ca, Updated 2023-07-13 ↗) The Special Drugs Program will cover costs for the above drugs if the patient: is an Ontario resident has a valid Ontario Health Insurance (OHIP) has one of the diseases or conditions covered meets the established clinical criteria is under the care of an approved physician/designated care centre (ontario.ca, Updated 2023-07-13 ↗)
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Clozaril Tablet · DIN 00894737 Manufacturer: Novartis Pharma Canada Inc.; listing date 2007-09-04 Health Canada: Marketed since 2016-04-08 · brand CLOZARIL · ATC N05AH02 CLOZAPINE · form Tablet · route Oral · ingredients CLOZAPINE 25 MG · company Hls therapeutics inc · schedule Prescription
Check this DIN again · Health Canada product record

Clozaril Tablet: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=11422 · Verify on the e-Formulary ↗ (DIN 00894737)

Source record
DIN 00894737: Clozaril Tablet Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 281608157; group id 486; item number 1242; lccId None; manufacturer id NOV Source form: None; strength: 25mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00894737 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=11422
Interchangeable products
AA-Clozapine Tablet · DIN 02248034 · not recorded Gen-Clozapine ODT · DIN 02554658 · not recorded Gen-Clozapine Tablet · DIN 02247243 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00894737
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Gen-Clozapine ODT · DIN 02554658 · 25mg ·

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-19
Special Drugs ProgramSpecial Drugs Program: Clozapine for treatment of schizophrenia (ontario.ca, Updated 2023-07-13 ↗) Through the Special Drugs Program, the Ministry of Health covers the full cost of certain outpatient drugs used in the treatment of specific conditions. (ontario.ca, Updated 2023-07-13 ↗) The Special Drugs Program will cover costs for the above drugs if the patient: is an Ontario resident has a valid Ontario Health Insurance (OHIP) has one of the diseases or conditions covered meets the established clinical criteria is under the care of an approved physician/designated care centre (ontario.ca, Updated 2023-07-13 ↗)
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Gen-Clozapine ODT · DIN 02554658 Manufacturer: Mylan Pharmaceuticals ULC; listing date 2026-02-27 Health Canada: Marketed since 2025-05-29 · brand GEN-CLOZAPINE · ATC N05AH02 CLOZAPINE · form Tablet (orally-disintegrating) · route Oral · ingredients CLOZAPINE 25 MG · company Mylan pharmaceuticals ulc · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104348 · Verify on the e-Formulary ↗ (DIN 02554658)

Source record
DIN 02554658: Gen-Clozapine ODT Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 281608157; group id 486; item number 1242; lccId None; manufacturer id MYL Source form: None; strength: 25mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $0.6594; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02554658 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104348
Interchangeable products
AA-Clozapine Tablet · DIN 02248034 · not recorded Clozaril Tablet · DIN 00894737 · not recorded Gen-Clozapine Tablet · DIN 02247243 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02554658
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Gen-Clozapine Tablet · DIN 02247243 · 25mg ·

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Special Drugs ProgramSpecial Drugs Program: Clozapine for treatment of schizophrenia (ontario.ca, Updated 2023-07-13 ↗) Through the Special Drugs Program, the Ministry of Health covers the full cost of certain outpatient drugs used in the treatment of specific conditions. (ontario.ca, Updated 2023-07-13 ↗) The Special Drugs Program will cover costs for the above drugs if the patient: is an Ontario resident has a valid Ontario Health Insurance (OHIP) has one of the diseases or conditions covered meets the established clinical criteria is under the care of an approved physician/designated care centre (ontario.ca, Updated 2023-07-13 ↗)
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Gen-Clozapine Tablet · DIN 02247243 Manufacturer: Mylan Pharmaceuticals ULC; listing date 2007-09-04 Health Canada: Marketed since 2010-02-09 · brand GEN-CLOZAPINE · ATC N05AH02 CLOZAPINE · form Tablet · route Oral · ingredients CLOZAPINE 25 MG · company Mylan pharmaceuticals ulc · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=71485 · Verify on the e-Formulary ↗ (DIN 02247243)

Source record
DIN 02247243: Gen-Clozapine Tablet Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 281608157; group id 486; item number 1242; lccId None; manufacturer id MYL Source form: None; strength: 25mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $0.6594; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02247243 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=71485
Interchangeable products
AA-Clozapine Tablet · DIN 02248034 · not recorded Clozaril Tablet · DIN 00894737 · not recorded Gen-Clozapine ODT · DIN 02554658 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02247243
Shortage record checked 2026-09-13T08:10:21.292534+00:00

AA-Clozapine Tablet · DIN 02458748 · 50mg ·

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Special Drugs ProgramSpecial Drugs Program: Clozapine for treatment of schizophrenia (ontario.ca, Updated 2023-07-13 ↗) Through the Special Drugs Program, the Ministry of Health covers the full cost of certain outpatient drugs used in the treatment of specific conditions. (ontario.ca, Updated 2023-07-13 ↗) The Special Drugs Program will cover costs for the above drugs if the patient: is an Ontario resident has a valid Ontario Health Insurance (OHIP) has one of the diseases or conditions covered meets the established clinical criteria is under the care of an approved physician/designated care centre (ontario.ca, Updated 2023-07-13 ↗)
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
AA-Clozapine Tablet · DIN 02458748 Manufacturer: A A Pharma Inc.; listing date 2021-12-17 Health Canada: Marketed since 2017-02-27 · brand AA-CLOZAPINE · ATC N05AH02 CLOZAPINE · form Tablet · route Oral · ingredients CLOZAPINE 50 MG · company Aa pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94589 · Verify on the e-Formulary ↗ (DIN 02458748)

Source record
DIN 02458748: AA-Clozapine Tablet Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 281608351; group id 486; item number 1240; lccId None; manufacturer id AAP Source form: None; strength: 50mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $1.3206; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02458748 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94589
Interchangeable products
Clozaril Tablet · DIN 02490668 · not recorded Gen-Clozapine ODT · DIN 02554666 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02458748
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Clozaril Tablet · DIN 02490668 · 50mg ·

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Special Drugs ProgramSpecial Drugs Program: Clozapine for treatment of schizophrenia (ontario.ca, Updated 2023-07-13 ↗) Through the Special Drugs Program, the Ministry of Health covers the full cost of certain outpatient drugs used in the treatment of specific conditions. (ontario.ca, Updated 2023-07-13 ↗) The Special Drugs Program will cover costs for the above drugs if the patient: is an Ontario resident has a valid Ontario Health Insurance (OHIP) has one of the diseases or conditions covered meets the established clinical criteria is under the care of an approved physician/designated care centre (ontario.ca, Updated 2023-07-13 ↗)
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Clozaril Tablet · DIN 02490668 Manufacturer: HLS Therapeutics Inc.; listing date 2021-12-17 Health Canada: Marketed since 2019-12-18 · brand CLOZARIL · ATC N05AH02 CLOZAPINE · form Tablet · route Oral · ingredients CLOZAPINE 50 MG · company Hls therapeutics inc · schedule Prescription
Check this DIN again · Health Canada product record

Clozaril Tablet: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98072 · Verify on the e-Formulary ↗ (DIN 02490668)

Source record
DIN 02490668: Clozaril Tablet Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 281608351; group id 486; item number 1240; lccId None; manufacturer id HLS Source form: None; strength: 50mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02490668 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98072
Interchangeable products
AA-Clozapine Tablet · DIN 02458748 · not recorded Gen-Clozapine ODT · DIN 02554666 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02490668
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Gen-Clozapine ODT · DIN 02554666 · 50mg ·

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Special Drugs ProgramSpecial Drugs Program: Clozapine for treatment of schizophrenia (ontario.ca, Updated 2023-07-13 ↗) Through the Special Drugs Program, the Ministry of Health covers the full cost of certain outpatient drugs used in the treatment of specific conditions. (ontario.ca, Updated 2023-07-13 ↗) The Special Drugs Program will cover costs for the above drugs if the patient: is an Ontario resident has a valid Ontario Health Insurance (OHIP) has one of the diseases or conditions covered meets the established clinical criteria is under the care of an approved physician/designated care centre (ontario.ca, Updated 2023-07-13 ↗)
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Gen-Clozapine ODT · DIN 02554666 Manufacturer: Mylan Pharmaceuticals ULC; listing date 2026-02-27 Health Canada: Marketed since 2025-05-29 · brand GEN-CLOZAPINE · ATC N05AH02 CLOZAPINE · form Tablet (orally-disintegrating) · route Oral · ingredients CLOZAPINE 50 MG · company Mylan pharmaceuticals ulc · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104349 · Verify on the e-Formulary ↗ (DIN 02554666)

Source record
DIN 02554666: Gen-Clozapine ODT Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 281608351; group id 486; item number 1240; lccId None; manufacturer id MYL Source form: None; strength: 50mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $1.3188; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02554666 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104349
Interchangeable products
AA-Clozapine Tablet · DIN 02458748 · not recorded Clozaril Tablet · DIN 02490668 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02554666
Shortage record checked 2026-09-13T08:10:21.292534+00:00

AA-Clozapine Tablet · DIN 02248035 · 100mg ·

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Special Drugs ProgramSpecial Drugs Program: Clozapine for treatment of schizophrenia (ontario.ca, Updated 2023-07-13 ↗) Through the Special Drugs Program, the Ministry of Health covers the full cost of certain outpatient drugs used in the treatment of specific conditions. (ontario.ca, Updated 2023-07-13 ↗) The Special Drugs Program will cover costs for the above drugs if the patient: is an Ontario resident has a valid Ontario Health Insurance (OHIP) has one of the diseases or conditions covered meets the established clinical criteria is under the care of an approved physician/designated care centre (ontario.ca, Updated 2023-07-13 ↗)
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
AA-Clozapine Tablet · DIN 02248035 Manufacturer: A A Pharma Inc.; listing date 2007-09-04 Health Canada: Marketed since 2016-11-21 · brand AA-CLOZAPINE · ATC N05AH02 CLOZAPINE · form Tablet · route Oral · ingredients CLOZAPINE 100 MG · company Aa pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=72355 · Verify on the e-Formulary ↗ (DIN 02248035)

Source record
DIN 02248035: AA-Clozapine Tablet Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 281608158; group id 486; item number 1243; lccId None; manufacturer id AAP Source form: None; strength: 100mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $2.6446; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02248035 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=72355
Interchangeable products
Clozaril Tablet · DIN 00894745 · not recorded Gen-Clozapine ODT · DIN 02554674 · not recorded Gen-Clozapine Tablet · DIN 02247244 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02248035
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Clozaril Tablet · DIN 00894745 · 100mg ·

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Special Drugs ProgramSpecial Drugs Program: Clozapine for treatment of schizophrenia (ontario.ca, Updated 2023-07-13 ↗) Through the Special Drugs Program, the Ministry of Health covers the full cost of certain outpatient drugs used in the treatment of specific conditions. (ontario.ca, Updated 2023-07-13 ↗) The Special Drugs Program will cover costs for the above drugs if the patient: is an Ontario resident has a valid Ontario Health Insurance (OHIP) has one of the diseases or conditions covered meets the established clinical criteria is under the care of an approved physician/designated care centre (ontario.ca, Updated 2023-07-13 ↗)
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Clozaril Tablet · DIN 00894745 Manufacturer: Novartis Pharma Canada Inc.; listing date 2007-09-04 Health Canada: Marketed since 2016-04-08 · brand CLOZARIL · ATC N05AH02 CLOZAPINE · form Tablet · route Oral · ingredients CLOZAPINE 100 MG · company Hls therapeutics inc · schedule Prescription
Check this DIN again · Health Canada product record

Clozaril Tablet: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=11421 · Verify on the e-Formulary ↗ (DIN 00894745)

Source record
DIN 00894745: Clozaril Tablet Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 281608158; group id 486; item number 1243; lccId None; manufacturer id NOV Source form: None; strength: 100mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00894745 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=11421
Interchangeable products
AA-Clozapine Tablet · DIN 02248035 · not recorded Gen-Clozapine ODT · DIN 02554674 · not recorded Gen-Clozapine Tablet · DIN 02247244 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00894745
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Gen-Clozapine ODT · DIN 02554674 · 100mg ·

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Special Drugs ProgramSpecial Drugs Program: Clozapine for treatment of schizophrenia (ontario.ca, Updated 2023-07-13 ↗) Through the Special Drugs Program, the Ministry of Health covers the full cost of certain outpatient drugs used in the treatment of specific conditions. (ontario.ca, Updated 2023-07-13 ↗) The Special Drugs Program will cover costs for the above drugs if the patient: is an Ontario resident has a valid Ontario Health Insurance (OHIP) has one of the diseases or conditions covered meets the established clinical criteria is under the care of an approved physician/designated care centre (ontario.ca, Updated 2023-07-13 ↗)
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Gen-Clozapine ODT · DIN 02554674 Manufacturer: Mylan Pharmaceuticals ULC; listing date 2026-02-27 Health Canada: Marketed since 2025-05-29 · brand GEN-CLOZAPINE · ATC N05AH02 CLOZAPINE · form Tablet (orally-disintegrating) · route Oral · ingredients CLOZAPINE 100 MG · company Mylan pharmaceuticals ulc · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104350 · Verify on the e-Formulary ↗ (DIN 02554674)

Source record
DIN 02554674: Gen-Clozapine ODT Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 281608158; group id 486; item number 1243; lccId None; manufacturer id MYL Source form: None; strength: 100mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $2.6446; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02554674 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104350
Interchangeable products
AA-Clozapine Tablet · DIN 02248035 · not recorded Clozaril Tablet · DIN 00894745 · not recorded Gen-Clozapine Tablet · DIN 02247244 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02554674
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Gen-Clozapine Tablet · DIN 02247244 · 100mg ·

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Special Drugs ProgramSpecial Drugs Program: Clozapine for treatment of schizophrenia (ontario.ca, Updated 2023-07-13 ↗) Through the Special Drugs Program, the Ministry of Health covers the full cost of certain outpatient drugs used in the treatment of specific conditions. (ontario.ca, Updated 2023-07-13 ↗) The Special Drugs Program will cover costs for the above drugs if the patient: is an Ontario resident has a valid Ontario Health Insurance (OHIP) has one of the diseases or conditions covered meets the established clinical criteria is under the care of an approved physician/designated care centre (ontario.ca, Updated 2023-07-13 ↗)
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Gen-Clozapine Tablet · DIN 02247244 Manufacturer: Mylan Pharmaceuticals ULC; listing date 2007-09-04 Health Canada: Marketed since 2009-10-15 · brand GEN-CLOZAPINE · ATC N05AH02 CLOZAPINE · form Tablet · route Oral · ingredients CLOZAPINE 100 MG · company Mylan pharmaceuticals ulc · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=71486 · Verify on the e-Formulary ↗ (DIN 02247244)

Source record
DIN 02247244: Gen-Clozapine Tablet Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 281608158; group id 486; item number 1243; lccId None; manufacturer id MYL Source form: None; strength: 100mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $2.6446; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02247244 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=71486
Interchangeable products
AA-Clozapine Tablet · DIN 02248035 · not recorded Clozaril Tablet · DIN 00894745 · not recorded Gen-Clozapine ODT · DIN 02554674 · not recorded
Shortage status: avoided shortage; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02247244
Shortage record checked 2026-09-13T08:10:21.292534+00:00

AA-Clozapine Tablet · DIN 02458756 · 200mg ·

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Special Drugs ProgramSpecial Drugs Program: Clozapine for treatment of schizophrenia (ontario.ca, Updated 2023-07-13 ↗) Through the Special Drugs Program, the Ministry of Health covers the full cost of certain outpatient drugs used in the treatment of specific conditions. (ontario.ca, Updated 2023-07-13 ↗) The Special Drugs Program will cover costs for the above drugs if the patient: is an Ontario resident has a valid Ontario Health Insurance (OHIP) has one of the diseases or conditions covered meets the established clinical criteria is under the care of an approved physician/designated care centre (ontario.ca, Updated 2023-07-13 ↗)
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
AA-Clozapine Tablet · DIN 02458756 Manufacturer: A A Pharma Inc.; listing date 2021-12-17 Health Canada: Marketed since 2017-02-27 · brand AA-CLOZAPINE · ATC N05AH02 CLOZAPINE · form Tablet · route Oral · ingredients CLOZAPINE 200 MG · company Aa pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94590 · Verify on the e-Formulary ↗ (DIN 02458756)

Source record
DIN 02458756: AA-Clozapine Tablet Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 281608352; group id 486; item number 1241; lccId None; manufacturer id AAP Source form: None; strength: 200mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $5.2892; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02458756 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94590
Interchangeable products
Clozaril Tablet · DIN 02490676 · not recorded Gen-Clozapine ODT · DIN 02554682 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02458756
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Clozaril Tablet · DIN 02490676 · 200mg ·

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Special Drugs ProgramSpecial Drugs Program: Clozapine for treatment of schizophrenia (ontario.ca, Updated 2023-07-13 ↗) Through the Special Drugs Program, the Ministry of Health covers the full cost of certain outpatient drugs used in the treatment of specific conditions. (ontario.ca, Updated 2023-07-13 ↗) The Special Drugs Program will cover costs for the above drugs if the patient: is an Ontario resident has a valid Ontario Health Insurance (OHIP) has one of the diseases or conditions covered meets the established clinical criteria is under the care of an approved physician/designated care centre (ontario.ca, Updated 2023-07-13 ↗)
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Clozaril Tablet · DIN 02490676 Manufacturer: HLS Therapeutics Inc.; listing date 2021-12-17 Health Canada: Marketed since 2019-12-18 · brand CLOZARIL · ATC N05AH02 CLOZAPINE · form Tablet · route Oral · ingredients CLOZAPINE 200 MG · company Hls therapeutics inc · schedule Prescription
Check this DIN again · Health Canada product record

Clozaril Tablet: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98073 · Verify on the e-Formulary ↗ (DIN 02490676)

Source record
DIN 02490676: Clozaril Tablet Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 281608352; group id 486; item number 1241; lccId None; manufacturer id HLS Source form: None; strength: 200mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02490676 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98073
Interchangeable products
AA-Clozapine Tablet · DIN 02458756 · not recorded Gen-Clozapine ODT · DIN 02554682 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02490676
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Gen-Clozapine ODT · DIN 02554682 · 200mg ·

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Special Drugs ProgramSpecial Drugs Program: Clozapine for treatment of schizophrenia (ontario.ca, Updated 2023-07-13 ↗) Through the Special Drugs Program, the Ministry of Health covers the full cost of certain outpatient drugs used in the treatment of specific conditions. (ontario.ca, Updated 2023-07-13 ↗) The Special Drugs Program will cover costs for the above drugs if the patient: is an Ontario resident has a valid Ontario Health Insurance (OHIP) has one of the diseases or conditions covered meets the established clinical criteria is under the care of an approved physician/designated care centre (ontario.ca, Updated 2023-07-13 ↗)
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Gen-Clozapine ODT · DIN 02554682 Manufacturer: Mylan Pharmaceuticals ULC; listing date 2026-02-27 Health Canada: Marketed since 2025-05-29 · brand GEN-CLOZAPINE · ATC N05AH02 CLOZAPINE · form Tablet (orally-disintegrating) · route Oral · ingredients CLOZAPINE 200 MG · company Mylan pharmaceuticals ulc · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104351 · Verify on the e-Formulary ↗ (DIN 02554682)

Source record
DIN 02554682: Gen-Clozapine ODT Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 281608352; group id 486; item number 1241; lccId None; manufacturer id MYL Source form: None; strength: 200mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $5.2892; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02554682 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104351
Interchangeable products
AA-Clozapine Tablet · DIN 02458756 · not recorded Clozaril Tablet · DIN 02490676 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02554682
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (28:16:08 Tranquilizers) and how they are covered

Matched class: 28:16:08 Tranquilizers

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ARIPIPRAZOLE, ASENAPINE, BREXPIPRAZOLE, CARIPRAZINE, FLUPENTIXOL DECANOATE, FLUPENTIXOL DIHYDROCHLORIDE, PALIPERIDONE, PALIPERIDONE PALMITATE, PERICYAZINE, PIMOZIDE, ZIPRASIDONE HCL MONOHYDRATE, ZUCLOPENTHIXOL DECANOATE, ZUCLOPENTHIXOL DIHYDROCHLORIDE Some products covered without a code (check the product listing): ALPRAZOLAM, BROMAZEPAM, CHLORDIAZEPOXIDE, CHLORPROMAZINE, CLORAZEPATE DIPOTASSIUM, DIAZEPAM, FLUPHENAZINE HCL, HALOPERIDOL, HALOPERIDOL DECANOATE, LORAZEPAM, LOXAPINE SUCCINATE, LURASIDONE HYDROCHLORIDE, OLANZAPINE, OXAZEPAM, PERPHENAZINE, PROCHLORPERAZINE, QUETIAPINE, RISPERIDONE, TRIFLUOPERAZINE 28:16:08 Tranquilizers

ASENAPINE

· 2 products · General benefit · strengths: 5mg, 10mg · SL Tab

LOXAPINE SUCCINATE

· 8 products · Listed, not a benefit (4), General benefit (4) · strengths: 5mg, 10mg, 25mg, 50mg · Tab

OLANZAPINE

· 116 products · General benefit (99), Off-Formulary Interchangeable, not an ODB benefit (17) · strengths: 5mg, 10mg, 15mg, 20mg, 2.5mg, 7.5mg · Rapid Dissolve Tab, Tab

QUETIAPINE

· 128 products · General benefit (125), Off-Formulary Interchangeable, not an ODB benefit (3) · strengths: 50mg, 150mg, 200mg, 300mg, 400mg, 25mg, 100mg · ER Tab, Tab

ARIPIPRAZOLE

· 70 products · General benefit · strengths: 720mg/2.4mL, 960mg/3.2mL, 300mg/Vial, 400mg/Vial, 2mg, 5mg, 10mg, 15mg, 20mg, 30mg · Inj Sol-Pref Syr, Prolong-Rel Inj Pd-Vial Pk, Tab

BREXPIPRAZOLE

· 6 products · General benefit · strengths: 0.25mg, 0.5mg, 1mg, 2mg, 3mg, 4mg · Tab

CARIPRAZINE

· 4 products · General benefit · strengths: 1.5mg, 3mg, 4.5mg, 6mg · Cap

CHLORPROMAZINE

· 6 products · General benefit (3), Listed, not a benefit (3) · strengths: 25mg, 50mg, 100mg · Tab

FLUPENTIXOL DECANOATE

· 2 products · General benefit · strengths: 20mg/mL, 100mg/mL · Inj Sol-1mL Amp Pk

FLUPENTIXOL DIHYDROCHLORIDE

· 2 products · General benefit · strengths: 0.5mg, 3mg · Tab

FLUPHENAZINE HCL

· 6 products · Listed, not a benefit (3), General benefit (3) · strengths: 1mg, 2mg, 5mg · Tab

HALOPERIDOL

· 14 products · Listed, not a benefit (7), General benefit (7) · strengths: 5mg/mL, 0.5mg, 1mg, 2mg, 5mg, 10mg, 20mg · Inj Sol-1mL Pk, Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 28:16:08 and 21 more
Full class listing Related classes: 28:08:04 Nonsteroidal Anti-Inflammatory Agents, 28:08:08 Opiate Agonists, 28:08:12 Opiate Partial Agonists, 28:08:92 Miscellaneous Analgesics and Antipyretics, 28:16:04 Antidepressants, 28:16:12 Other Psychotropics, 28:36:08 Anticholinergic Agents, 28:36:20 Dopamine Receptor Agonists Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS CLOZARIL® (clozapine) tablet is indicated in the management of symptoms of treatment- resistant schizophrenia. In controlled clinical trials, clozapine was found to improve both positive and negative symptoms. Due to the significant risk of neutropenia and seizure associated with its use, clozapine should be limited to treatment-resistant schizophrenic patients who are non-responsive to, or intolerant of, conventional antipsychotic drugs. Non-responsiveness is defined as the lack of satisfactory clinical response, despite treatment with appropriate courses of at least two marketed chemically-unrelated antipsychotic drugs. Intolerance is defined as the inability to achieve adequate benefit with conventional antipsychotic drugs because of dose-limiting, intolerable adverse effects. Because of the significant risk of neutropenia and seizure, events which both present a continuing risk over time, the extended treatment of patients failing to show an acceptable level of clinical response to clozapine should ordinarily be avoided. Seizure risk is dose-related and is more likely to occur with rapid dose increases. Titrate gradually and use divided doses. Use with ca… https://pdf.hres.ca/dpd_pm/00081000.PDF PM date: not printed or not captured Source product: CLOZARIL; DIN 00894737; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Other review policies

For AA-Clozapine Tablet, Clozaril Tablet, Gen-Clozapine ODT, Gen-Clozapine Tablet: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026